Reported 2 months ago
Eli Lilly's stock experienced a significant increase after the company reported impressive second-quarter earnings that surpassed analyst predictions. The pharmaceutical giant also upgraded its full-year earnings and revenue forecast, attributing its success to robust sales of its GLP-1 medications, Mounjaro and Zepbound.
Source: YAHOO